Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.

Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A.

Cancer Immunol Immunother. 2013 Oct;62(10):1563-73. doi: 10.1007/s00262-013-1459-x.

PMID:
23903715
2.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.

Blood. 2011 Jan 20;117(3):808-14. doi: 10.1182/blood-2010-05-286286.

3.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009.

PMID:
23791878
4.

A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

Yang S, Dudley ME, Rosenberg SA, Morgan RA.

J Immunother. 2010 Jul-Aug;33(6):648-58. doi: 10.1097/CJI.0b013e3181e311cb.

PMID:
20551831
5.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

6.

Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.

Liao Y, Geng P, Tian Y, Miao H, Liang H, Zeng R, Ni B, Ruan Z.

Immunol Invest. 2015;44(2):147-63. doi: 10.3109/08820139.2014.944980.

PMID:
25122543
7.

MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.

Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L.

J Immunol. 2010 Jan 1;184(1):452-65. doi: 10.4049/jimmunol.0901101.

8.

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Kaiser AD, Gadiot J, Guislain A, Blank CU.

Cancer Immunol Immunother. 2013 Mar;62(3):503-15. doi: 10.1007/s00262-012-1350-1.

PMID:
23001162
10.

The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.

Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.

Sci Transl Med. 2012 Aug 29;4(149):149ra120. doi: 10.1126/scitranslmed.3004306.

11.

HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy.

Chakupurakal G, Onion D, Bonney S, Cobbold M, Mautner V, Moss P.

J Immunother. 2013 Oct;36(8):423-31. doi: 10.1097/CJI.0b013e3182a8029e.

PMID:
23994889
12.

Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

Matteucci E, Ghimenti M, Di Beo S, Giampietro O.

J Clin Immunol. 2011 Dec;31(6):977-84. doi: 10.1007/s10875-011-9573-z.

PMID:
21887518
13.

Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.

Bachmann MF, Wolint P, Schwarz K, Jäger P, Oxenius A.

J Immunol. 2005 Oct 1;175(7):4686-96.

14.

Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets.

Stemberger C, Neuenhahn M, Gebhardt FE, Schiemann M, Buchholz VR, Busch DH.

Semin Immunol. 2009 Apr;21(2):62-8. doi: 10.1016/j.smim.2009.02.004. Review.

PMID:
19269852
15.
16.

CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells.

Fiorentini S, Licenziati S, Alessandri G, Castelli F, Caligaris S, Bonafede M, Grassi M, Garrafa E, Balsari A, Turano A, Caruso A.

J Immunol. 2001 Jan 15;166(2):900-7.

17.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106.

18.

Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.

Distler E, Bloetz A, Albrecht J, Asdufan S, Hohberger A, Frey M, Schnürer E, Thomas S, Theobald M, Hartwig UF, Herr W.

Haematologica. 2011 Jul;96(7):1024-32. doi: 10.3324/haematol.2010.037481.

19.

TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.

Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.

J Immunother. 2010 May;33(4):371-81. doi: 10.1097/CJI.0b013e3181cd1180.

PMID:
20386469
20.

Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Díaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ, Lichtenheld MG.

Immunol Res. 2013 Dec;57(1-3):23-33. doi: 10.1007/s12026-013-8456-1.

PMID:
24218360
Items per page

Supplemental Content

Support Center